Literature DB >> 11401318

Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma.

M A Rumi1, H Sato, S Ishihara, K Kawashima, S Hamamoto, H Kazumori, T Okuyama, R Fukuda, N Nagasue, Y Kinoshita.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands have been implicated in the growth inhibition and differentiation of certain human cancers with diverse tissue origin. In this study, expression of PPARgamma in human hepatocellular carcinoma (HCC) and the effect of PPARgamma ligands on HCC cells were investigated in vitro using Hep G2, HuH-7, KYN-1 and KYN-2 cell lines. All cell lines were found to express functionally active PPARgamma and a marked growth inhibition was induced by thiazolidinedione ligands troglitazone, and pioglitazone as well as with its natural ligand 15-deoxy-Delta(12,14)-prostaglandin J(2). The growth inhibitory effect was associated with a dose-dependent inhibition of DNA synthesis, cell cycle progression and alpha fetoprotein expression. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11401318      PMCID： PMC2363681          DOI： 10.1054/bjoc.2001.1821

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  60 in total

1.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.

Authors:  Y F Guan; Y H Zhang; R M Breyer; L Davis; M D Breyer
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 2.  Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.

Authors:  J Kohlroser; J Mathai; J Reichheld; B F Banner; H L Bonkovsky
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

3.  Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer.

Authors:  T H Chang; E Szabo
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

4.  Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells.

Authors:  A Galli; D Crabb; D Price; E Ceni; R Salzano; C Surrenti; A Casini
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

5.  Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids.

Authors:  H Asou; W Verbeek; E Williamson; E Elstner; T Kubota; N Kamada; H P Koeffler
Journal:  Int J Oncol       Date:  1999-11       Impact factor: 5.650

6.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

7.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2.

Authors:  R Butler; S H Mitchell; D J Tindall; C Y Young
Journal:  Cell Growth Differ       Date:  2000-01

8.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis.

Authors:  Y Tsubouchi; H Sano; Y Kawahito; S Mukai; R Yamada; M Kohno; K Inoue; T Hla; M Kondo
Journal:  Biochem Biophys Res Commun       Date:  2000-04-13       Impact factor: 3.575

9.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

Authors:  T Kubota; K Koshizuka; E A Williamson; H Asou; J W Said; S Holden; I Miyoshi; H P Koeffler
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

10.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

Authors:  E Elstner; C Müller; K Koshizuka; E A Williamson; D Park; H Asou; P Shintaku; J W Said; D Heber; H P Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205
View more
  23 in total

1.  Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates.

Authors:  Julio Sevillano; Inmaculada C López-Pérez; Emilio Herrera; María Del Pilar Ramos; Carlos Bocos
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

2.  Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.

Authors:  Sylvia Stadlmann; Uwe Gueth; Edward Wight; Leoni A Kunz-Schughart; Arndt Hartmann; Gad Singer
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

3.  Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.

Authors:  Yan-Tong Guo; Xi-Sheng Leng; Tao Li; Jing-Ming Zhao; Xi-Hou Lin
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study.

Authors:  Shuji Sumie; Takumi Kawaguchi; Atsushi Kawaguchi; Ryoko Kuromatsu; Masahito Nakano; Manabu Satani; Shingo Yamada; Shusuke Okamura; Yuko Yonezawa; Tatsuyuki Kakuma; Takuji Torimura; Michio Sata
Journal:  Mol Clin Oncol       Date:  2014-10-06

5.  Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

Authors:  Chuanbing Zang; Marlies Wächter; Hongyu Liu; Maximilian G Posch; Martin H Fenner; Christine Stadelmann; Andreas von Deimling; Kurt Possinger; Keith L Black; H Phillip Koeffler; Elena Elstner
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

6.  Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis.

Authors:  Evan D Rosen; Rohit N Kulkarni; Pasha Sarraf; Umut Ozcan; Terumasa Okada; Chung-Hsin Hsu; Daniel Eisenman; Mark A Magnuson; Frank J Gonzalez; C Ronald Kahn; Bruce M Spiegelman
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells.

Authors:  Chan Woo Cheon; Dae Hwan Kim; Dong Heon Kim; Yong Hoon Cho; Jae Hun Kim
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

8.  Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.

Authors:  Weijun Ou; Rohit S Mulik; Arnida Anwar; Jeffrey G McDonald; Xiaoshun He; Ian R Corbin
Journal:  Free Radic Biol Med       Date:  2017-09-08       Impact factor: 7.376

9.  Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.

Authors:  Liang-qi Cao; Xiao-li Wang; Qian Wang; Ping Xue; Xing-yuan Jiao; He-ping Peng; Hai-wu Lu; Qiang Zheng; Xi-lin Chen; Xiao-hui Huang; Xin-hui Fu; Jing-song Chen
Journal:  Acta Pharmacol Sin       Date:  2009-08-17       Impact factor: 6.150

10.  Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma.

Authors:  D Vara; C Morell; N Rodríguez-Henche; I Diaz-Laviada
Journal:  Cell Death Dis       Date:  2013-05-02       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.